Search - tctmd.com

Displaying 1 - 20 of 114

Sort: Relevancy | Date

News Conference News ACC 2025

AI Shows Promise in Detecting Type 1 MI and Need for Revascularization

Yael L. Maxwell

April 07, 2025

News Conference News ACC 2025

DETECT-AS: Alert System Increases AV Replacement in Eligible Patients

Michael O'Riordan

April 04, 2025

News Conference News ACC 2025

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

L.A. McKeown

April 03, 2025

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

News Conference News ACC 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Michael O'Riordan

April 01, 2025

News Conference News ACC 2025

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

Caitlin E. Cox

March 31, 2025

News Conference News ACC 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

L.A. McKeown

March 30, 2025

News Conference News ACC 2025

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Yael L. Maxwell

March 30, 2025

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

Caitlin E. Cox

March 30, 2025

News Conference News ACC 2025

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

Michael O'Riordan

March 30, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

News Daily News ACC 2025

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

L.A. McKeown

March 29, 2025

News Conference News ACC 2025

WARRIOR: No Clear Answers on How to Best Treat INOCA

Yael L. Maxwell

March 29, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

L.A. McKeown

April 16, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Conference News ACC 2024

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

Caitlin E. Cox

April 10, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

Another Win for TAVI in Low-to-Intermediate Risk Patients

News Conference News ACC 2024

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

Yael L. Maxwell

April 08, 2024

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

Advertisement

AI Shows Promise in Detecting Type 1 MI and Need for Revascularization

DETECT-AS: Alert System Increases AV Replacement in Eligible Patients

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

WARRIOR: No Clear Answers on How to Best Treat INOCA

What’s Going to Be Hot at ACC 2025?

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content